© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
New molecular entities
New molecular entities
Nexavar
Sorafenib tablets
Bayer/OnyxORAL THERAPY APPROVED FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA
New indications
Avelox
Moxifloxacin
Bayer/Schering-PloughFLUOROQUINOLONE ANTIBIOTIC APPROVED FOR CIAI
Dosing. The recommended dose of moxifloxacin is 400 mg (orally or as an IV infusion) once every 24 hours. For cIAIs, therapy should usually be initiated with the IV formulation, and the duration of therapy should last from 5 to 14 days.